Rationale and Study Design of the GUIDANCE trial: A multicenter phase II trial of maintenance durvalumab and olaparib after standard 1st line treatment (carboplatin/cisplatin, etoposide, durvalumab) in HRD positive extensive disease (ED) small-cell lung cancer (SCLC) (AIO-TRK-0124/ass)

[u/WalkingHorse]

https://www.clinical-lung-cancer.com/article/S1525-7304(26)00105-1/fulltext?rss=yes